---
title: "Rare Disease Differential Diagnosis with Large Language Models at Scale: From Abdominal Actinomycosis to Wilson's Disease"
summary: "ëŒ€ê·œëª¨ ì–¸ì–´ ëª¨ë¸ ê¸°ë°˜ í¬ê·€ ì§ˆí™˜ ì§„ë‹¨ ì‹œìŠ¤í…œ RareScale ê°œë°œ: ì „ë¬¸ê°€ ì‹œìŠ¤í…œê³¼ ê²°í•©, ì§„ë‹¨ ì •í™•ë„ 17% í–¥ìƒ"
categories: ["AI Generated", "ğŸ¤— Daily Papers"]
tags: ["Natural Language Processing", "Large Language Models", "ğŸ¢ Curai Health",]
showSummary: true
date: 2025-02-20
draft: false
---

<br>

{{< keywordList >}}
{{< keyword icon="fingerprint" >}} 2502.15069 {{< /keyword >}}
{{< keyword icon="writer" >}} Elliot Schumacher et el. {{< /keyword >}}
 
{{< keyword >}} ğŸ¤— 2025-02-24 {{< /keyword >}}
 
{{< /keywordList >}}

{{< button href="https://arxiv.org/abs/2502.15069" target="_self" >}}
â†— arXiv
{{< /button >}}
{{< button href="https://huggingface.co/papers/2502.15069" target="_self" >}}
â†— Hugging Face
{{< /button >}}




### TL;DR


{{< lead >}}

ì˜ë£Œ í˜„ì¥ì—ì„œ í¬ê·€ ì§ˆí™˜ ì§„ë‹¨ì€ í™˜ìì˜ ì¥ê¸°ê°„ ê³ í†µê³¼ ì˜ë£Œ ìì› ë‚­ë¹„ë¥¼ ì´ˆë˜í•˜ëŠ” ì–´ë ¤ìš´ ë¬¸ì œì…ë‹ˆë‹¤. ê¸°ì¡´ì˜ ì „ë¬¸ê°€ ì‹œìŠ¤í…œì€ í™œìš©ì´ ì–´ë µê³  í¬ê·€ ì§ˆí™˜ì— ëŒ€í•œ ì§€ì‹ì´ ë¶€ì¡±í•œ í•œê³„ë¥¼ ì§€ë‹ˆê³  ìˆìŠµë‹ˆë‹¤.  ìµœê·¼ ëŒ€ê·œëª¨ ì–¸ì–´ ëª¨ë¸(LLM)ì´ ì˜ë£Œ ë¶„ì•¼ì—ì„œ ì£¼ëª©ë°›ê³  ìˆìœ¼ë‚˜, í¬ê·€ ì§ˆí™˜ ì§„ë‹¨ì— ëŒ€í•œ ì„±ëŠ¥ì€ ì•„ì§ ë¯¸í¡í•œ ì‹¤ì •ì…ë‹ˆë‹¤.

ë³¸ ì—°êµ¬ëŠ” ì´ëŸ¬í•œ ë¬¸ì œë¥¼ í•´ê²°í•˜ê¸° ìœ„í•´ **LLMê³¼ ì „ë¬¸ê°€ ì‹œìŠ¤í…œì„ ê²°í•©í•œ ìƒˆë¡œìš´ í¬ê·€ ì§ˆí™˜ ì§„ë‹¨ ì‹œìŠ¤í…œì¸ RareScaleì„ ì œì•ˆ**í•©ë‹ˆë‹¤. RareScaleì€ ì „ë¬¸ê°€ ì‹œìŠ¤í…œì˜ ì§€ì‹ê³¼ LLMì˜ ì¼ë°˜ì ì¸ ì§„ë‹¨ ëŠ¥ë ¥ì„ ê²°í•©í•˜ì—¬ í¬ê·€ ì§ˆí™˜ ì§„ë‹¨ ì •í™•ë„ë¥¼ í–¥ìƒì‹œí‚¤ëŠ” ê²ƒì„ ëª©í‘œë¡œ í•©ë‹ˆë‹¤.  **575ê°œ ì´ìƒì˜ í¬ê·€ ì§ˆí™˜**ì„ ëŒ€ìƒìœ¼ë¡œ ì‹¤í—˜í•œ ê²°ê³¼, RareScaleì€ ê¸°ì¡´ LLM ê¸°ë°˜ ì‹œìŠ¤í…œë³´ë‹¤ **ì§„ë‹¨ ì •í™•ë„ë¥¼ 17% ì´ìƒ í–¥ìƒ**ì‹œí‚¤ëŠ” ì„±ê³¼ë¥¼ ê±°ë‘ì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” **ì˜ë£Œ AI ë¶„ì•¼ì˜ ë°œì „ì— í¬ê²Œ ê¸°ì—¬**í•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€ë©ë‹ˆë‹¤.

{{< /lead >}}


#### Key Takeaways

{{< alert "star" >}}
{{< typeit speed=10 lifeLike=true >}} RareScaleì€ LLMê³¼ ì „ë¬¸ê°€ ì‹œìŠ¤í…œì„ ê²°í•©í•˜ì—¬ í¬ê·€ ì§ˆí™˜ ì§„ë‹¨ ì •í™•ë„ë¥¼ í–¥ìƒì‹œì¼°ë‹¤. {{< /typeit >}}
{{< /alert >}}

{{< alert "star" >}}
{{< typeit speed=10 startDelay=1000 lifeLike=true >}} RareScaleì€ 575ê°€ì§€ ì´ìƒì˜ í¬ê·€ ì§ˆí™˜ì— ëŒ€í•œ ì§„ë‹¨ ì„±ëŠ¥ì„ í‰ê°€í•˜ì—¬ ìœ ì˜ë¯¸í•œ ì„±ê³¼ë¥¼ ë‹¬ì„±í–ˆë‹¤. {{< /typeit >}}
{{< /alert >}}

{{< alert "star" >}}
{{< typeit speed=10 startDelay=2000 lifeLike=true >}} ë³¸ ì—°êµ¬ëŠ” í¬ê·€ ì§ˆí™˜ ì§„ë‹¨ ë¶„ì•¼ì˜ ìƒˆë¡œìš´ ì—°êµ¬ ë°©í–¥ì„ ì œì‹œí•˜ê³  í–¥í›„ ì˜ë£Œ AI ë°œì „ì— ê¸°ì—¬í•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€ëœë‹¤. {{< /typeit >}}
{{< /alert >}}

#### Why does it matter?
ë³¸ ë…¼ë¬¸ì€ **í¬ê·€ ì§ˆí™˜ ì§„ë‹¨ì˜ ì–´ë ¤ì›€ì„ í•´ê²°í•˜ê¸° ìœ„í•œ í˜ì‹ ì ì¸ ì ‘ê·¼ë²•**ì„ ì œì‹œí•˜ì—¬, ì˜ë£Œ AI ë¶„ì•¼ì˜ ë°œì „ì— í¬ê²Œ ê¸°ì—¬í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. **ëŒ€ê·œëª¨ ì–¸ì–´ ëª¨ë¸(LLM)ê³¼ ì „ë¬¸ê°€ ì‹œìŠ¤í…œì„ ê²°í•©**í•˜ì—¬ í¬ê·€ ì§ˆí™˜ ì§„ë‹¨ ì •í™•ë„ë¥¼ í–¥ìƒì‹œí‚¨ ì—°êµ¬ ê²°ê³¼ëŠ” **ì˜ë£Œ ì„œë¹„ìŠ¤ ì§ˆ í–¥ìƒ ë° ì˜ë£Œë¹„ ì ˆê°**ì—ë„ í° ì˜í–¥ì„ ë¯¸ì¹  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ë˜í•œ, ë³¸ ì—°êµ¬ì—ì„œ ì œì‹œëœ **RareScale ëª¨ë¸ì€ í–¥í›„ í¬ê·€ ì§ˆí™˜ ì§„ë‹¨ ë¶„ì•¼ ì—°êµ¬ì˜ ìƒˆë¡œìš´ ë°©í–¥**ì„ ì œì‹œí•˜ë©°, ë‹¤ì–‘í•œ ì˜ë£Œ AI ëª¨ë¸ ê°œë°œ ë° ì‘ìš© ì—°êµ¬ì— ì¤‘ìš”í•œ **ì§€ì¹¨**ì„ ì œê³µí•  ê²ƒì…ë‹ˆë‹¤.

------
#### Visual Insights



![](https://arxiv.org/html/2502.15069/extracted/6205376/images/rare_disease.002.png)

> ğŸ”¼ RareScaleì€ í¬ê·€ ì§ˆë³‘ ì§„ë‹¨ì„ ê°œì„ í•˜ê¸° ìœ„í•œ ì„¸ ê°€ì§€ ë‹¨ê³„ ì ‘ê·¼ ë°©ì‹ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ë¨¼ì €, ì „ë¬¸ê°€ ì‹œìŠ¤í…œê³¼ LLMì„ ê²°í•©í•˜ì—¬ í¬ê·€ ì§ˆë³‘ ê´€ë ¨ ëŒ€í™” ì½”í¼ìŠ¤ë¥¼ ì‹œë®¬ë ˆì´ì…˜í•©ë‹ˆë‹¤. ë‹¤ìŒìœ¼ë¡œ, ì´ ë°ì´í„°ë¥¼ ì‚¬ìš©í•˜ì—¬ í›„ë³´ ì§ˆë³‘ ìƒì„± LLMì„ í›ˆë ¨í•©ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ì´ ëª¨ë¸ì„ ì‚¬ìš©í•˜ì—¬ ìµœì¢… ê°ë³„ ì§„ë‹¨(DDx)ì„ ìƒì„±í•©ë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Figure 1: An overview of RareScale. Our approach consists of three stages. First, we simulate a corpus of rare disease chats ( Â§3 and Figure 2). Then, we train a candidate generation LLM (Â§4.1). Finally, we perform inference to generate a final DDx (Â§4.2).
> </details>





{{< table-caption >}}
| Differential Diagnosis | gpt-4o test set (n=3403) |  |  | claude test set (n=2868) |  |  |
|---|---|---|---|---|---|---|
|  | Top-5 | Top -1 | MRR | Top-5 | Top -1 | MRR |
|---|---|---|---|---|---|---|
| **baseline** | 56.80% | 28.65% | 0.390 | 56.69% | 30.65% | 0.406 |
| **gpt-4o rare candidates** | 52.66% | 25.95% | 0.357 | 55.47% | 29.04% | 0.388 |
| **RareScale candidates** | **74.38%** | **33.12%** | **0.471** | **71.41%** | **33.23%** | **0.461** |{{< /table-caption >}}

> ğŸ”¼ í‘œ 1ì€ RareScaleì„ ì‚¬ìš©í•˜ì—¬ ìƒì„±ëœ GPT-40 ê°ë³„ ì§„ë‹¨ ê²°ê³¼ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤.  ë‘ ë°ì´í„°ì…‹ ëª¨ë‘ì—ì„œ RareScaleì˜ ëª¨ë“  ì§€í‘œëŠ” í›„ë³´êµ° ì—†ì´ ì§„í–‰í•œ ê¸°ì¤€ì„  ëŒ€ë¹„ ìœ ì˜ë¯¸í•œ ì°¨ì´ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤ (ì–‘ì¸¡ Wilcoxon ë¶€í˜¸ ìˆœìœ„ ê²€ì •, p<0.01).  ì¦‰, RareScale ëª¨ë¸ì´ ê°ë³„ ì§„ë‹¨ ì •í™•ë„ë¥¼ í–¥ìƒì‹œì¼°ìŒì„ ë³´ì—¬ì¤ë‹ˆë‹¤.  Top-1 ì •í™•ë„, Top-5 ì •í™•ë„, ê·¸ë¦¬ê³  MRR(Mean Reciprocal Rank) ê°’ì„ í†µí•´ ëª¨ë¸ ì„±ëŠ¥ì„ í‰ê°€í•˜ì˜€ìŠµë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Table 1: Performance on generated gpt-4o ddx task. All metrics for RareScale on both datasets (see bolded) are significant using a two-sided Wilcoxon signed-rank test with p<0.01ğ‘0.01p<0.01italic_p < 0.01 compared to the no candidates baseline.
> </details>





### In-depth insights


#### Rare Disease LLMs
ë³¸ ë…¼ë¬¸ì€ í¬ê·€ ì§ˆí™˜ ì§„ë‹¨ì— ëŒ€ê·œëª¨ ì–¸ì–´ ëª¨ë¸(LLM)ì„ ì ìš©í•˜ëŠ” í˜ì‹ ì ì¸ ì ‘ê·¼ ë°©ì‹ì„ ì œì‹œí•©ë‹ˆë‹¤. **í¬ê·€ ì§ˆí™˜ì€ ì¦ìƒì´ ëª¨í˜¸í•˜ê³  ìœ ë³‘ë¥ ì´ ë‚®ì•„ ì§„ë‹¨ì´ ì–´ë µê¸° ë•Œë¬¸ì—** ê¸°ì¡´ì˜ ì˜ë£Œ ì‹œìŠ¤í…œìœ¼ë¡œëŠ” íš¨ê³¼ì ì¸ ì§„ë‹¨ì´ ì–´ë ¤ìš´ ê²½ìš°ê°€ ë§ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë¬¸ì œë¥¼ í•´ê²°í•˜ê¸° ìœ„í•´, ë³¸ ì—°êµ¬ëŠ” **ì „ë¬¸ê°€ ì‹œìŠ¤í…œê³¼ LLMì„ ê²°í•©í•˜ì—¬ í¬ê·€ ì§ˆí™˜ í›„ë³´ë¥¼ ì œì•ˆí•˜ê³  ìµœì¢… ì§„ë‹¨ì„ ë‚´ë¦¬ëŠ” RareScaleì´ë¼ëŠ” ì‹œìŠ¤í…œ**ì„ ì œì•ˆí•©ë‹ˆë‹¤. RareScaleì€ í¬ê·€ ì§ˆí™˜ì— ëŒ€í•œ ì „ë¬¸ê°€ ì§€ì‹ê³¼ LLMì˜ ì¼ë°˜ì ì¸ ì§„ë‹¨ ëŠ¥ë ¥ì„ ê²°í•©í•˜ì—¬ ê¸°ì¡´ì˜ LLM ê¸°ë°˜ ì§„ë‹¨ ì‹œìŠ¤í…œë³´ë‹¤ ì„±ëŠ¥ì„ í–¥ìƒì‹œì¼°ìŠµë‹ˆë‹¤. **íŠ¹íˆ, í¬ê·€ ì§ˆí™˜ ë°ì´í„°ì…‹ì„ ìƒì„±í•˜ê¸° ìœ„í•´ ì „ë¬¸ê°€ ì‹œìŠ¤í…œê³¼ ì˜ë£Œ ì‚¬ë¡€ ì‹œë®¬ë ˆì´í„°ë¥¼ ì‚¬ìš©í•˜ì—¬ ë‹¤ì–‘í•œ í¬ê·€ ì§ˆí™˜ ëŒ€í™”ë¥¼ ìƒì„±**í•˜ì—¬ ëª¨ë¸ì˜ í•™ìŠµ ë° í‰ê°€ë¥¼ ìˆ˜í–‰í•œ ì ì´ ì£¼ëª©í•  ë§Œí•©ë‹ˆë‹¤.  **RareScaleì€ ì˜ë£Œ ì„œë¹„ìŠ¤ ì ‘ê·¼ì„±ì„ í–¥ìƒì‹œí‚¤ê³  í¬ê·€ ì§ˆí™˜ ì§„ë‹¨ì˜ íš¨ìœ¨ì„±ì„ ë†’ì´ëŠ” ë° ê¸°ì—¬**í•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€ë©ë‹ˆë‹¤. í•˜ì§€ë§Œ,  **ì „ë¬¸ê°€ ì‹œìŠ¤í…œì˜ ì œí•œëœ í¬ê·€ ì§ˆí™˜ ë°ì´í„°ì™€ LLMì˜ í•œê³„**ëŠ” í–¥í›„ ì—°êµ¬ì—ì„œ ê°œì„ í•´ì•¼ í•  ê³¼ì œì…ë‹ˆë‹¤.

#### RareScale Pipeline
RareScale íŒŒì´í”„ë¼ì¸ì€ **í¬ê·€ ì§ˆí™˜ ì§„ë‹¨ì˜ ì •í™•ë„ë¥¼ ë†’ì´ê¸° ìœ„í•´** ì „ë¬¸ê°€ ì‹œìŠ¤í…œê³¼ ëŒ€ê·œëª¨ ì–¸ì–´ ëª¨ë¸(LLM)ì„ ê²°í•©í•œ ì ‘ê·¼ ë°©ì‹ì…ë‹ˆë‹¤.  **ì „ë¬¸ê°€ ì‹œìŠ¤í…œì˜ ì§€ì‹**ì„ í™œìš©í•˜ì—¬ í¬ê·€ ì§ˆí™˜ í™˜ìì˜ ëŒ€í™”ë¥¼ ì‹œë®¬ë ˆì´ì…˜í•˜ê³ , ì´ë¥¼ í†µí•´ í›ˆë ¨ëœ í¬ê·€ ì§ˆí™˜ í›„ë³´ ì˜ˆì¸¡ ëª¨ë¸ì€ **LLMì˜ ì¼ë°˜ì ì¸ ì§„ë‹¨ ëŠ¥ë ¥**ê³¼ ê²°í•©í•˜ì—¬ ìµœì¢… ì§„ë‹¨ì„ ë‚´ë¦½ë‹ˆë‹¤.  **í¬ê·€ ì§ˆí™˜ê³¼ í”í•œ ì§ˆí™˜ì˜ ê· í˜•**ì„ ë§ì¶”ëŠ” ê²ƒì´ í•µì‹¬ìœ¼ë¡œ, ë‹¨ìˆœíˆ LLMë§Œ ì‚¬ìš©í•˜ëŠ” ê²½ìš°ë³´ë‹¤ ì •í™•ë„ë¥¼ í¬ê²Œ í–¥ìƒì‹œí‚¤ëŠ” ê²ƒì„ ëª©í‘œë¡œ í•©ë‹ˆë‹¤.  **ì˜ë£Œ í˜„ì¥ì˜ ì œì•½**ì„ ê³ ë ¤í•˜ì—¬, ì‹¤ì œ ì ìš© ê°€ëŠ¥ì„±ì„ ë†’ì´ëŠ” ë°©ì•ˆë„ í•¨ê»˜ ëª¨ìƒ‰í•˜ê³  ìˆìŠµë‹ˆë‹¤.

#### Synthetic Data
ë³¸ ë…¼ë¬¸ì—ì„œ ë‹¤ë£¬ í•©ì„± ë°ì´í„°ëŠ” **í¬ê·€ ì§ˆí™˜ ì§„ë‹¨**ì— ì´ˆì ì„ ë§ì¶˜ ì˜ë£Œ ëŒ€í™” ì‹œë®¬ë ˆì´ì…˜ ë°ì´í„°ì…‹ì„ ìƒì„±í•˜ëŠ” ë° ì‚¬ìš©ë˜ì—ˆìŠµë‹ˆë‹¤. ì „ë¬¸ê°€ ì‹œìŠ¤í…œê³¼ ëŒ€ê·œëª¨ ì–¸ì–´ ëª¨ë¸(LLM)ì„ ê²°í•©í•˜ì—¬ êµ¬ì¶•ëœ ì´ ë°ì´í„°ì…‹ì€ ì˜ì‚¬ì™€ í™˜ì ê°„ì˜ ìƒí˜¸ ì‘ìš©ì„ ì‹œë®¬ë ˆì´ì…˜í•˜ì—¬ í¬ê·€ ì§ˆí™˜ì˜ ì¦ìƒê³¼ ë³‘ë ¥ì„ ë°˜ì˜í•©ë‹ˆë‹¤. ì´ë¥¼ í†µí•´ **LLMì˜ í¬ê·€ ì§ˆí™˜ ì§„ë‹¨ ì„±ëŠ¥ì„ í‰ê°€í•˜ê³  ê°œì„ **í•˜ëŠ” ë° ì¤‘ìš”í•œ ì—­í• ì„ í•©ë‹ˆë‹¤.  **ì „ë¬¸ê°€ ì‹œìŠ¤í…œì˜ ì§€ì‹**ì„ í™œìš©í•˜ì—¬ ì‹¤ì œ ì˜ë£Œ ë°ì´í„°ì˜ ë¶€ì¡±í•¨ì„ ë³´ì™„í•˜ê³ , ë” ë‚˜ì•„ê°€ **LLMì˜ í•™ìŠµ ë°ì´í„°ë¥¼ í™•ì¥**ì‹œí‚¤ëŠ” ë° ê¸°ì—¬í•©ë‹ˆë‹¤. ë°ì´í„° ìƒì„± ê³¼ì •ì€ ì „ë¬¸ê°€ ì‹œìŠ¤í…œì˜ ì§€ì‹ê³¼ LLMì˜ ìì—°ì–´ ì²˜ë¦¬ ëŠ¥ë ¥ì„ í™œìš©í•˜ì—¬, ë‹¤ì–‘í•˜ê³  í˜„ì‹¤ì ì¸ ì˜ë£Œ ëŒ€í™” ì‹œë‚˜ë¦¬ì˜¤ë¥¼ ë§Œë“¤ì–´ë‚´ëŠ” ë° ì„±ê³µì ì´ì—ˆìŠµë‹ˆë‹¤.  í•˜ì§€ë§Œ **ë°ì´í„°ì˜ ê· í˜•** ë° ì‹¤ì œ ì„ìƒ ë°ì´í„°ì™€ì˜ ì •í•©ì„±ì— ëŒ€í•œ ì¶”ê°€ì ì¸ ê²€í† ê°€ í•„ìš”í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.

#### Model Fusion
ë…¼ë¬¸ì—ì„œ 'ëª¨ë¸ ìœµí•©'ì´ë¼ëŠ” ì œëª©ì˜ ë‚´ìš©ì„ ë¶„ì„í•´ ë³´ë©´, **LLMì˜ ê°•ì ê³¼ ì „ë¬¸ê°€ ì‹œìŠ¤í…œì˜ ì§€ì‹ì„ ê²°í•©í•˜ì—¬ ì§„ë‹¨ ì •í™•ë„ë¥¼ ë†’ì´ëŠ” ì „ëµ**ì„ì„ ì•Œ ìˆ˜ ìˆìŠµë‹ˆë‹¤.  ì´ëŠ” ë‹¨ìˆœíˆ LLMì„ ì‚¬ìš©í•˜ëŠ” ê²ƒë³´ë‹¤ **í¬ê·€ ì§ˆí™˜ ì§„ë‹¨ì— ìˆì–´ì„œ ì •í™•ì„±ê³¼ íš¨ìœ¨ì„±ì„ í¬ê²Œ í–¥ìƒ**ì‹œí‚¤ëŠ” íš¨ê³¼ì ì¸ ë°©ë²•ì…ë‹ˆë‹¤.  **LLMì˜ ì¼ë°˜ì ì¸ ì˜í•™ ì§€ì‹ê³¼ ì „ë¬¸ê°€ ì‹œìŠ¤í…œì˜ í¬ê·€ ì§ˆí™˜ ê´€ë ¨ ì „ë¬¸ ì§€ì‹ì„ í†µí•©**í•¨ìœ¼ë¡œì¨, í”í•œ ì§ˆë³‘ê³¼ í¬ê·€ ì§ˆë³‘ ê°„ì˜ ê°ë³„ ì§„ë‹¨ì´ ê°€ëŠ¥í•´ì§‘ë‹ˆë‹¤.  íŠ¹íˆ, í¬ê·€ ì§ˆí™˜ì˜ ê²½ìš° ì¦ìƒì´ ëª¨í˜¸í•˜ê±°ë‚˜ ë‹¤ë¥¸ ì§ˆë³‘ê³¼ ì¤‘ë³µë  ìˆ˜ ìˆì–´ ê°ë³„ ì§„ë‹¨ì´ ì–´ë ¤ìš´ë°, ëª¨ë¸ ìœµí•©ì€ ì´ëŸ¬í•œ ì–´ë ¤ì›€ì„ í•´ê²°í•˜ëŠ” ë° ì¤‘ìš”í•œ ì—­í• ì„ í•©ë‹ˆë‹¤.  **RareScaleê³¼ ê°™ì€ ëª¨ë¸ ìœµí•© ì‹œìŠ¤í…œì€ ì˜ë£Œ í˜„ì¥ì—ì„œ ì˜ì‚¬ì˜ íŒë‹¨ì„ ì§€ì›í•˜ê³ , í™˜ìì˜ ì§„ë‹¨ ì‹œê°„ì„ ë‹¨ì¶•í•˜ëŠ” ë° ê¸°ì—¬**í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.  í•˜ì§€ë§Œ, **ì „ë¬¸ê°€ ì‹œìŠ¤í…œì˜ ì§€ì‹ ê¸°ë°˜ êµ¬ì¶• ë° LLMì˜ ì„±ëŠ¥ í–¥ìƒì€ ì§€ì†ì ì¸ ì—°êµ¬ ê°œë°œì´ í•„ìš”**í•œ ë¶€ë¶„ì…ë‹ˆë‹¤.

#### Future Work
ë³¸ ë…¼ë¬¸ì€ í¬ê·€ ì§ˆí™˜ ì§„ë‹¨ì„ ìœ„í•œ RareScale ì‹œìŠ¤í…œì„ ì œì•ˆí•˜ì§€ë§Œ, **ì—¬ì „íˆ ê°œì„ ì˜ ì—¬ì§€ê°€ ë§ë‹¤.**  **í–¥í›„ ì—°êµ¬ ë°©í–¥**ìœ¼ë¡œëŠ” ë¨¼ì €, **ë”ìš± ë°©ëŒ€í•œ í¬ê·€ ì§ˆí™˜ ë°ì´í„°ì…‹ êµ¬ì¶•**ì´ í•„ìš”í•˜ë‹¤. í˜„ì¬ ì‚¬ìš©ëœ ì „ë¬¸ê°€ ì‹œìŠ¤í…œì˜ ì§€ì‹ ê¸°ë°˜ì€ ì œí•œì ì´ë¯€ë¡œ,  **ë‹¤ì–‘í•œ í¬ê·€ ì§ˆí™˜ì„ í¬ê´„í•˜ëŠ” ëŒ€ê·œëª¨ ë°ì´í„°ì…‹ í™•ë³´**ë¥¼ í†µí•´ ëª¨ë¸ì˜ ì¼ë°˜í™” ì„±ëŠ¥ì„ í–¥ìƒì‹œì¼œì•¼ í•œë‹¤.  ë˜í•œ, **ì „ë¬¸ê°€ ì‹œìŠ¤í…œê³¼ LLMì˜ í†µí•© ë°©ì‹ ê°œì„ **ë„ ì¤‘ìš”í•˜ë‹¤. í˜„ì¬ëŠ” ë‹¨ìˆœíˆ í›„ë³´êµ° ìƒì„±ì— ì „ë¬¸ê°€ ì‹œìŠ¤í…œì„ í™œìš©í•˜ì§€ë§Œ, **LLMì˜ ì¶”ë¡  ê³¼ì •ì— ì „ë¬¸ê°€ ì§€ì‹ì„ ë³´ë‹¤ íš¨ê³¼ì ìœ¼ë¡œ í†µí•©**í•˜ëŠ” ë°©ë²•ì„ ëª¨ìƒ‰í•´ì•¼ í•œë‹¤.  ë§ˆì§€ë§‰ìœ¼ë¡œ, **ì„ìƒ í˜„ì¥ì—ì„œì˜ ì‹¤ì œ í™œìš©ì„±ì„ ê²€ì¦**í•˜ê¸° ìœ„í•œ ì—°êµ¬ê°€ í•„ìš”í•˜ë‹¤.  **ì‹¤ì œ ì˜ë£Œ ë°ì´í„°ë¥¼ í™œìš©í•œ í‰ê°€**ë¥¼ í†µí•´ RareScaleì˜ ìœ ìš©ì„±ì„ í™•ì¸í•˜ê³ , ì˜ë£Œ í˜„ì¥ì˜ ìš”êµ¬ì‚¬í•­ì„ ë°˜ì˜í•˜ì—¬ ì‹œìŠ¤í…œì„ ê°œì„ í•´ì•¼ í•œë‹¤. ì´ë¥¼ í†µí•´ **ì‹¤ì§ˆì ì¸ ì˜ë£Œ í˜„ì¥ ì ìš© ê°€ëŠ¥ì„±**ì„ ë†’ì¼ ìˆ˜ ìˆë‹¤.


### More visual insights




<details>
<summary>More on tables
</summary>


{{< table-caption >}}
| DDx LLM | Exact | Extremely Rel. | Relevant | Somewhat Rel. | Unrelated |
|---|---|---|---|---|---| 
| **baseline gpt-4o** | 22.8% | 19.9% | 4.9% | 21.0% | 31.3% |
| **RareScale gpt-4o** | 55.8% | 8.8% | 2.3% | 12.8% | 20.2% |
| **baseline claude** | 19.2% | 16.9% | 3.9% | 14.5% | 45.6% |
| **RareScale claude** | 56.8% | 10.7% | 1.6% | 10.6% | 20.4% |
| **baseline Llama 3.3 70b** | 20.3% | 19.3% | 5.3% | 21.7% | 33.5% |
| **RareScale Llama 3,3 70b** | 47.3% | 12.2% | 3.3% | 15.4% | 21.9% |{{< /table-caption >}}
> ğŸ”¼ í‘œ 2ëŠ” RareScale í›„ë³´êµ°ì„ ì¶”ê°€í•œ LLMê³¼ ì¶”ê°€í•˜ì§€ ì•Šì€ LLMì˜ DDx ìƒì„± ì„±ëŠ¥ì„ ë¹„êµí•œ ê²°ê³¼ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤. 'ì™„ë²½ ì¼ì¹˜'ë¶€í„° 'ë¬´ê´€'ê¹Œì§€ ë‹¤ì–‘í•œ ìœ ì‚¬ì„± ë²”ì£¼ì— ê±¸ì³ LLM íŒì • ê²°ê³¼ë¥¼ ì œì‹œí•˜ë©°, gpt-4o ë° claude í…ŒìŠ¤íŠ¸ ì„¸íŠ¸ì˜ ê²°ê³¼ë¥¼ í†µí•©í•˜ì—¬ ë¶„ì„í•©ë‹ˆë‹¤.  RareScaleì´ DDx ì •í™•ë„ë¥¼ í–¥ìƒì‹œí‚¤ëŠ” ë° ê¸°ì—¬í•˜ëŠ”ì§€, ê·¸ë¦¬ê³  ì–´ë–¤ ìœ ì‚¬ì„± ë²”ì£¼ì—ì„œ ì„±ëŠ¥ í–¥ìƒì´ ë‘ë“œëŸ¬ì§€ëŠ”ì§€ë¥¼ ë³´ì—¬ì£¼ëŠ” í‘œì…ë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Table 2: We compare LLM baseline DDx generation performance to LLMs with addition of RareScale candidates. We report the LLM as judge results across several categories of similarity, ranging from Exact Match to Unrelated. We combine gpt-4o and claude test sets for this analysis.
> </details>

{{< table-caption >}}
| Training Dataset | Training Size | gpt-4o test set (n=3403) Top-5 | gpt-4o test set (n=3403) Top-1 | gpt-4o test set (n=3403) MRR | claude test set (n=2868) Top-5 | claude test set (n=2868) Top-1 | claude test set (n=2868) MRR |
|---|---|---|---|---|---|---|---| 
| **claude** | 8837 | 48.37% | 34.12% | 0.4007 | 64.92% | 45.64% | 0.5371 |
| **gpt-4o** | 21782 | 88.04% | 63.88% | 0.7410 | 44.18% | 28.45% | 0.3490 |
| **gpt-4o downsampled** | 8813 | 70.88% | 47.90% | 0.5742 | 37.20% | 23.25% | 0.2884 |
| **gpt-4o + claude** | 30619 | 88.80% | 64.21% | 0.7463 | 77.82% | 56.35% | 0.6526 |{{< /table-caption >}}
> ğŸ”¼ í‘œ 3ì€ í›„ë³´ ìƒì„± ì‘ì—…ì— ëŒ€í•œ í‰ê°€ ê²°ê³¼ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤. MRR, ìƒìœ„ 5ê°œ, ìƒìœ„ 1ê°œ ì •í™•ë„ë¥¼ ì‚¬ìš©í•˜ì—¬ í‰ê°€í–ˆìŠµë‹ˆë‹¤.  Claude ë°ì´í„°, gpt-4o ë°ì´í„°, ê·¸ë¦¬ê³  ë‘ ë°ì´í„° ëª¨ë‘ë¥¼ ì‚¬ìš©í•˜ì—¬ í›ˆë ¨ëœ ëª¨ë¸ì„ í‰ê°€í•˜ê³ , Claude ë° gpt-4o í…ŒìŠ¤íŠ¸ ì„¸íŠ¸ì—ì„œ ë³„ë„ë¡œ í‰ê°€í–ˆìŠµë‹ˆë‹¤.  Claude í›ˆë ¨ ì„¸íŠ¸ì˜ í¬ê¸°ì™€ ìœ ì‚¬í•˜ë„ë¡ ë‹¤ìš´ìƒ˜í”Œë§ëœ gpt-4o ë°ì´í„° ì„¸íŠ¸ë¥¼ ì‚¬ìš©í•˜ì—¬ í›ˆë ¨ëœ ëª¨ë¸ë„ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Table 3: Evaluation on the candidate generation task, with MRR, Top-5 and Top-1 Accuracy. We evaluate on models only trained on claude data, gpt-4o data, and both, and evaluate separately on claude and gpt-4o test sets. We include a model trained on a downsampled set of gpt-4o data that approximates the size of the claude training set.
> </details>

{{< table-caption >}}
| Dx Category | Top K Accuracy | Top 1 Accuracy | MRR | N |
|---|---|---|---|---|
| Congenital disorders due to abnormal fetal development | 0.533 | 0.433 | 0.458 | 30 |
| Immune system disorders | 0.548 | 0.190 | 0.295 | 42 |
| End organ damage secondary to other disorders | 0.583 | 0.083 | 0.222 | 36 |
| Disorders with excess or abnormal fluid accumulation | 0.603 | 0.256 | 0.370 | 78 |
| Disorders of the hematopoietic and lymphatic systems | 0.667 | 0.000 | 0.306 | 6 |
| Drug induced injury alias adverse drug effects | 0.699 | 0.192 | 0.361 | 73 |
| Degenerative disorders | 0.704 | 0.241 | 0.391 | 108 |
| Infectious disease alias infections | 0.711 | 0.278 | 0.424 | 862 |
| Neoplastic disease | 0.721 | 0.236 | 0.384 | 330 |
| Disorders involving cysts stones or calculi | 0.722 | 0.611 | 0.650 | 18 |
| Impaired cardiovascular function | 0.738 | 0.359 | 0.486 | 390 |
| Disorders due to toxic or chemical or radiation injury | 0.745 | 0.398 | 0.523 | 98 |
| Musculoskeletal disorders | 0.750 | 0.292 | 0.467 | 24 |
| Non-infectious inflammatory disease | 0.753 | 0.326 | 0.477 | 384 |
| Metabolic disorders | 0.778 | 0.333 | 0.482 | 144 |
| Bleeding disorders and coagulopathies | 0.783 | 0.267 | 0.449 | 60 |
| Disorders of thorax cardiovascular system and lymphatic ducts | 0.783 | 0.522 | 0.590 | 23 |
| Endocrine disease | 0.788 | 0.417 | 0.547 | 132 |
| Fibrosis or scarring of visceral organ | 0.796 | 0.245 | 0.436 | 49 |
| Neuropsychiatric disorders | 0.803 | 0.439 | 0.573 | 66 |
| Disorders secondary to trauma | 0.806 | 0.361 | 0.519 | 36 |
| Impaired fluid flow within hollow viscus or viscera non-vascular | 0.833 | 0.583 | 0.649 | 24 |
| Multisystem disorders | 0.833 | 0.667 | 0.708 | 6 |
| Disorders associated with pregnancy | 0.833 | 0.542 | 0.663 | 24 |
| Inherited congenital or degenerative disorders | 0.847 | 0.458 | 0.588 | 144 |
| Miscellaneous mechanical disorders | 0.861 | 0.542 | 0.655 | 72 |
| Kidney and urinary tract disorders | 0.875 | 0.458 | 0.654 | 24 |
| Disorders due to mechanical tear or trauma or visceral erosion | 0.875 | 0.667 | 0.764 | 24 |
| Disorders of abdomen digestive system and/or nutrition | 0.889 | 0.389 | 0.573 | 18 |
| Disorders due to nutritional and/or vitamin deficiency | 0.917 | 0.611 | 0.738 | 36 |
| Electrophysiological neurological disorders | 0.917 | 0.542 | 0.687 | 24 |
| Disorders of smooth muscle contraction and/or relaxation | 0.944 | 0.722 | 0.801 | 18 |{{< /table-caption >}}
> ğŸ”¼ í‘œ 4ëŠ” RareScale ëª¨ë¸ì˜ ì„±ëŠ¥ì„ ì§ˆë³‘ ë²”ì£¼ë³„ë¡œ ì„¸ë¶„í™”í•˜ì—¬ ë³´ì—¬ì¤ë‹ˆë‹¤. ì´ í‘œëŠ” ë³¸ ë…¼ë¬¸ì˜ í‘œ 1ì—ì„œ gpt-40ë¥¼ ì‚¬ìš©í•œ RareScale ëª¨ë¸ì˜ ì„±ëŠ¥ì„ ê¸°ë°˜ìœ¼ë¡œ í•˜ë©°, ê° ì§ˆë³‘ì´ ì—¬ëŸ¬ ë²”ì£¼ì— ì†í•  ìˆ˜ ìˆë‹¤ëŠ” ì ì„ ëª…ì‹œí•˜ê³  ìˆìŠµë‹ˆë‹¤.  ê° ì§ˆë³‘ ë²”ì£¼ì— ëŒ€í•´ Top-K ì •í™•ë„, Top-1 ì •í™•ë„, MRR(Mean Reciprocal Rank) ê°’ê³¼ ë°ì´í„° ìˆ˜(N)ì„ ì œì‹œí•˜ì—¬ RareScale ëª¨ë¸ì´ ë‹¤ì–‘í•œ ì§ˆë³‘ ë²”ì£¼ì—ì„œ ì–´ëŠ ì •ë„ì˜ ì„±ëŠ¥ì„ ë³´ì´ëŠ”ì§€ ìƒì„¸íˆ ë¶„ì„í•œ ê²°ê³¼ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Table 4: Performance from RareScale, gpt-4o in Table 1 broken down by disease category. Note that a disease may fall into multiple categories.
> </details>

{{< table-caption >}}
| generation model | split | size | findings | messages |
|---|---|---|---|---|
| **gpt-4o** | train | 21782 | 11.88 Â± 1.91 | 17.54 Â± 3.58 |
|  | val | 3404 | 11.69 Â± 2.08 | 17.31 Â± 3.78 |
|  | test | 3403 | 11.66 Â± 2.05 | 17.27 Â± 3.69 |
| **claude** | train | 8837 | 11.88 Â± 1.90 | 14.54 Â± 3.47 |
|  | val | 2868 | 11.69 Â± 2.04 | 14.11 Â± 3.38 |
|  | test | 2868 | 11.70 Â± 2.08 | 14.30 Â± 3.48 |{{< /table-caption >}}
> ğŸ”¼ í‘œ 5ëŠ” í›ˆë ¨, ê²€ì¦ ë° í…ŒìŠ¤íŠ¸ ì„¸íŠ¸ì— ëŒ€í•œ í†µê³„ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤.  ì„¸íŠ¸ì˜ ì±„íŒ… ìˆ˜, í‰ê·  ë°œê²¬ ìˆ˜ì™€ í‘œì¤€ í¸ì°¨, ê·¸ë¦¬ê³  í‰ê·  ë©”ì‹œì§€ ìˆ˜ì™€ í‘œì¤€ í¸ì°¨ë¥¼ í¬í•¨í•©ë‹ˆë‹¤. ì´ëŠ” ëª¨ë¸ í›ˆë ¨ ë° í‰ê°€ì— ì‚¬ìš©ëœ ë°ì´í„°ì˜ í¬ê¸°ì™€ ë‹¤ì–‘ì„±ì„ ì´í•´í•˜ëŠ” ë° ë„ì›€ì´ ë©ë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Table 5: Data statistics for train, validation, and test sets. We include the number of chats, the average number of findings and standard deviation, and the average number of messages and standard deviation.
> </details>

{{< table-caption >}}
| Synthetic | Annotator | Disease | Reasoning |
|---|---|---|---| 
| yes | yes | histoplasma meningitis | This disease is possible because the patientâ€™s history of lymphoma and transplant makes them immunocompromised, which increases their risk of histoplasmosis meningitis. The histoplasmosis meningitis could cause this patientâ€™s symptoms of nausea/vomiting, fever/chills, and severe headache. |
| yes | yes | cerebral malaria | This disease is possible because urinary and bowel incontinence, intractable headache, visual loss/retinopathy, and fever point to an infectious cerebral process that could be caused by cerebral malaria. |
| yes | yes | neurogenic osteoarthropathy alias charcot_joint_disease | This could be possible charcot joint disease, which is set off by trauma to a neuropathic extremity and can cause joint pain. Although Charcotâ€™s is technically most common in the foot, it can also extend to any major joint like the knees, shoulder, hip, etc. |
| yes | yes | glaucoma acute angle closure | Blurriness with rainbow rings/halos, nausea/vomiting, headache, decreased vision, and sudden onset are all symptoms of acute angle-closure glaucoma. |
| yes | yes | cytomegalovirus infection disseminated | This disease is possible because the patient is immunocompromised by their organ transplant, and their symptoms of vision changes, diarrhea, fever, chills, vomiting, and myalgias are consistent with a disseminated cytomegalovirus infection. |
| yes | no | cutaneous anthrax | Lack of bump/ulcer/eschar. though presence of pruritis and exposure to possible animals infected as a vet, symptoms are nonspecific. |
| yes | no | herpes zoster | This disease is not possible because although herpes zoster can have peripheral symptoms including this patientâ€™s myalgia, headache, and abdominal pain, this patient does not have the characteristic dermatomal rash, skin changes, or skin-level pain of herpes zoster. |
| no | no | pulmonary aspergillosis invasive type | This disease is not possible because the patient is not immunocompromised, has not had recent surgeries or pneumonia, or chemotherapy, and does not have a cough, which I would expect from pulmonary aspergillosis since it is an opportunistic pulmonary infection. |
| no | no | henoch schonlein syndrome alias henoch-schonlein purpura | This disease is not possible because the patient does not report the purpura around the legs/gluteus that is characteristic for Henoch Schonlein purpura. The patient is also not in the typical age group for this disease, which primarily is in pediatric populations. |
| no | yes | bronchial asthma | This disease is possible because of the patientâ€™s history of dyspnea at rest and worse with activity. The urinary frequency could also be related because there are positive associations between bronchial asthma and increased urge to urinate. |{{< /table-caption >}}
> ğŸ”¼ í‘œ 6ì€ ì£¼ì„ ì‘ì—…ì—ì„œ ë‚˜ì˜¨ ìƒ˜í”Œ ì„¤ëª…ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ì§ˆë³‘ ì—´ì´ ì–´ë–¤ ì§ˆë³‘ì„ ì£¼ì„ ì²˜ë¦¬í•˜ë„ë¡ ìš”ì²­ë°›ì•˜ëŠ”ì§€ ë‚˜íƒ€ë‚´ëŠ” ê²ƒì„ ì°¸ê³ í•˜ì„¸ìš”. ì–‘ì„± í•©ì„± ë ˆì´ë¸”ì˜ ê²½ìš° ì˜ˆìƒ ì§ˆë³‘ì´ê³ , ìŒì„±ì˜ ê²½ìš° ì˜ˆìƒë˜ì§€ ì•ŠìŠµë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Table 6: Sample explanations from the annotation task. Note that the disease column indicates which disease they were asked to annotate against â€“ this is the expected disease for the positive synthetic labels, but is not expected for the negative ones.
> </details>

{{< table-caption >}}
|                     | **gpt-4o chats** |                     |                     |                     | **claude chats** |                     |                     |
| :------------------ | :----------------: | :----------------: | :----------------: | :----------------: | :----------------: | :----------------: | :----------------: |
| **gpt-4o only**    |      88.28%       |      63.13%       |      0.7384       |      47.25%       |      31.80%       |      0.3817       |
| **claude only**   |      48.38%       |      34.43%       |      0.4025       |      65.93%       |      45.71%       |      0.5415       |
| **combined**       |      88.57%       |      64.10%       |      0.7444       |      79.64%       |      57.46%       |      0.6675       |
| Top K              |     Top-1          |      MRR           |  Top K              |      Top-1          |      MRR          |{{< /table-caption >}}
> ğŸ”¼ í‘œ 7ì€ ê²€ì¦ ì„¸íŠ¸ì— ëŒ€í•œ í›„ë³´ ìƒì„± ì§€í‘œë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤.  gpt-40 ì „ìš©, claude ì „ìš©, ê·¸ë¦¬ê³  ë‘ ëª¨ë¸ì„ ê²°í•©í•œ ê²½ìš°ì— ëŒ€í•œ ìƒìœ„ 1ê°œ, ìƒìœ„ 5ê°œ ì •í™•ë„ ë° MRR(í‰ê·  ì—­ìˆœìœ„) ì ìˆ˜ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤. ì´ í‘œëŠ” RareScale ëª¨ë¸ì˜ í›„ë³´ ìƒì„± ì„±ëŠ¥ì„ í‰ê°€í•˜ëŠ” ë° ì‚¬ìš©ë©ë‹ˆë‹¤.
> <details>
> <summary>read the caption</summary>
> Table 7: Candidate generation metrics for validation set.
> </details>

</details>




### Full paper

{{< gallery >}}
<img src="paper_images/1.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/2.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/3.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/4.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/5.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/6.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/7.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/8.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/9.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/10.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/11.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/12.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/13.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/14.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/15.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/16.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/17.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/18.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/19.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
<img src="paper_images/20.png" class="grid-w50 md:grid-w33 xl:grid-w25" />
{{< /gallery >}}